EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Fc Cavity Conjugation Improves Developability and In Vivo Efficacy of Antibody Drug Conjugates

Yuichi Imura, Keisuke Nagai, Hiroki Azuma, Takashi Kurita, Chika Kaneda, Fuuka Seki, Ayano Izumi, Momoko Komesu, Naritoshi Shirata, Kaori Murakoshi

Bioconjugate Chemistry · 12.11.2026

DOI: 10.1021/acs.bioconjchem.6c00541 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioconjugate Chemistry, online erschienen am 12.11.2026. Verfasst von Yuichi Imura und 9 weiteren Autor:innen. Die Arbeit nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Tanabe Pharma Corporation.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Antibody drug conjugates (ADCs) are a promising class of therapeutics in cancer treatment. However, the general design principles of ADCs are yet to be established. We hypothesized that shielding the linker payload within the Fc cavity could mitigate premature exposure of linker payloads during systemic circulation and improve in vivo efficacy. To achieve this goal, we employed engineered cysteines and screened conjugation sites to find an optimal site which can mask a payload in the Fc cavity. Through a cathepsin cleavage assay and hydrophobic interaction chromatography, several conjugation sites were identified to produce drug-to-antibody ratio (DAR) 2 Fc cavity ADCs. Among the identified sites, V264C exhibited the strongest payload-shielding effect. Using a molecular-ruler approach, we further quantified the payload-accommodating capacity of each Fc cavity conjugation site and found substantial site-dependent differences in cavity size. The single mutations were further combined to generate DAR4 ADCs, leading to the identification of a practical site selection guideline for engineered cysteine-based DAR4 Fc cavity ADCs. An intermutation distance of ∼ 20 Å emerged as a practical threshold for selecting compatible mutation pairs in DAR4 Fc cavity ADCs. Both the DAR2 and DAR4 Fc cavity ADCs showed improved in vivo efficacy compared with the randomly conjugated ADCs.

Förderung

  • Tanabe Pharma Corporation

Zitieren

APA

Imura, Y., Nagai, K., Azuma, H., Kurita, T., Kaneda, C., Seki, F., Izumi, A., Komesu, M., Shirata, N., & Murakoshi, K. (2026). Fc Cavity Conjugation Improves Developability and In Vivo Efficacy of Antibody Drug Conjugates. Bioconjugate Chemistry. https://doi.org/10.1021/acs.bioconjchem.6c00541

Vancouver

Imura Y, Nagai K, Azuma H, Kurita T, Kaneda C, Seki F, et al. Fc Cavity Conjugation Improves Developability and In Vivo Efficacy of Antibody Drug Conjugates. Bioconjugate Chemistry. 2026. doi:10.1021/acs.bioconjchem.6c00541

BibTeX
@article{Imura2026,
  author = {Imura, Yuichi and Nagai, Keisuke and Azuma, Hiroki and Kurita, Takashi and Kaneda, Chika and Seki, Fuuka and Izumi, Ayano and Komesu, Momoko and Shirata, Naritoshi and Murakoshi, Kaori},
  title = {Fc Cavity Conjugation Improves Developability and In Vivo Efficacy of Antibody Drug Conjugates},
  journal = {Bioconjugate Chemistry},
  year = {2026},
  doi = {10.1021/acs.bioconjchem.6c00541}
}
Kostenlos starten →